Objectives: To summarise the experience and evaluate the performance of the Ontario maternal serum screening (MSS) programme.
S econ d trimester maternal serum screening (MSS) for Down's syndrome and open neural tube defects (ONTD) was first introduced into clinical practice in the late 1980s. Using triple maternal serum markers -alphafetoprotein (MSAFP), unconjugated oestriol (MSuE3) and human chorionic gonadotrophin (MShCG) in combination with maternal age, 60-69% of fetuses with Down's syndrome can be detected in the second trimester with a false-positive rate of 5%. 1 The screen also detects 80% of fetuses with ONTD with a false-positive rate of about 2%.2 A later study showed that the levels of these three markers were significantly lower in women with trisomy 18 pregnancies, resulting in the development of screening for this disorder."" In July 1993, the Ministry of Health of the Province of Ontario funded a MSS programme. As part of the programme, a MSS database was established to audit screening performance, including pregnancy outcomes. This database is the largest outcome-based MSS database in the world. Using information collected in the MSS database, the current study evaluates the performance of MSS in Ontario.
METHODS
The maternal serum screen used three biochemical markers -MSAFP, MSuE3 and MShCG -in combination with maternal age to estimate a woman's risk at term of having a fetus with Down's syndrome and/or trisomy 18. It also estimates a woman's risk of having a fetus with ONTD based www.jmedscreen.com on the measurement of MSAFP. The serum markers were expressed as multiples of the median levels (MoM) of unaffected pregnancies of the same gestational age. Since the levels of maternal serum markers are influenced by maternal weight, ethnicity and maternal diabetes mellitus, marker levels were adjusted for these parameters as appropriate.t" Women had blood samples for MSS taken between IS and 20 weeks of pregnancy. The biochemical assays were undertaken in seven regional laboratories across Ontario. The gestational age at the time of blood sampling was estimated by fetal biparietal diameter (BPD) or crown-rump length (CRL) on ultrasound scan, or the date of last menstrual period (LMP). Gestational age was revised based on scan dating when the discrepancy between scan dating and LMP exceeded nine days. If gestational dating was revised, the initial date was not retained by the screening software. The risks for Down's syndrome, trisomy 18 and ONTD were calculated using MSAFP Expert (Benetech, ON, Canada). Published risk calculation parameters were used in our programme':" and were not changed during the study period. The risk cut-off for Down's syndrome was ;;.1 in 385 at term, and for ONTD was an MSAFP ;;'2.2 MoM. Fixed analyte cut-offs (0.75, 0.60 and 0.55 MoM for MSAFP, MSuE3 and MShCG, respectively) were used for trisomy 18 in the first several years. This was changed to a risk calculation with a cut-off of ;;.1 in 100 at term after this improved screening method was described." The implementation date of the risk cut-off method varied between centres, but all centres were using this method by May of 1999.
As with other MSS programmes, screening performance is described in terms of detection rate (DR), false-positive rate (FPR) and odds of being affected given a positive result (OAPR). The DR (sensitivity) is the proportion of affected pregnancies with screen-positive results. The FPR (I -specificity) is the proportion of unaffected pregnancies with screenpositive results. The OAPR is the ratio of affected to unaffected pregnancies with positive test results. The DR at term was estimated from the sum of screen-positive births and the screen-positive terminations allowing for spontaneous fetal losses divided by the sum of total affected births and terminations allowing for spontaneous fetal losses. The fetal loss rates between amniocentesis and term were assumed as 23% for Down's syndrome and 68% for trisomy 18. 9
The information collected in the MSS database includes utilisation, screening results, follow-up data and pregnancy outcomes. The demographic information and test results of all screened pregnancies were routinely collected in an electronic format, according to uniform guidelines at each of the seven regional testing centres in Ontario. Data on utilisation of follow-up genetic services and pregnancy outcomes of initial screen-positive pregnancies were collected from 21 genetic centres in a paper format and entered into the MSS database by a trained medical records technologist. Data on utilisation of hospital services and outcome for all pregnancies screened were obtained through the Canadian Institute of Health Information (C!HI), which records every hospital admission in Canada. The ICD-9 coding system was used to define pregnancy outcomes. Where necessary, information was verified through provincial genetic centres and cytogenetic laboratories.
Following the introduction of the MSS programme, there was a trial period of three months to allow the individual regional centres to implement the screening programme. At the time this report was written, the MSS database had received pregnancy outcome data from CIHI for women screened before the end of September 2000. The results of Summers, Farrell, Huang, et 0/.
the current study are based on all women screened between 1 October 1993 and 30 September 2000 in the province of Ontario.
RESULTS

Utilisation of MSS
Between I October 1993 and 30 September 2000, 428,4 10 women residing in Ontario were screened for ONTD and 423,895 women were screened for Down's syndrome and trisomy 18. Pregnancy outcomes were available for 94.8% of all women screened. The median age at the expected date of delivery for women screened in the programme was 30 years. Among women screened for Down's syndrome, 68,831 (16.2%) were aged ;;"35 years. Seventy-five percent of women screened were Caucasian, 19% were Asian and 6% were Afro-Caribbean. Approximately 48% of all pregnant women in the province had MSS. Among women aged ;;,,35 years, 52% had MSS; this rate was 47% for women <35 years. The uptake rate of MSS varied substantially across the province, with over 60% uptake in the city of Toronto, and just under 20% in Northern Ontario. Table 1 shows the screening performance for Down's syndrome in different years during the study period. Of the 717 cases of Down's syndrome ascertained in the screened population in the seven-year study period, 531 were detected by MSS. The screening programme achieved a term detection rate of 70.6%, with a false-positive rate of 7.2%. For every 60 women with a screen-positive result for Down's syndrome, one fetus with Down's syndrome would be diagnosed. Table 2 compares the screening performance for Down's syndrome for women aged <35 and ;;,,35 years at the expected date of delivery. Of 423,854 women screened and 
Screening performance for Down's syndrome
Utilisation of amniocentesis for detection of Down's syndrome
Amniocentesis is routinely offered to all women with a screen-positive result for Down's syndrome or trisomy 18. In Canada, women aged~35 years are eligible to have amniocentesis." Figure I shows the uptake rates of amniocentesis following a positive MSS result for women <35 and~35 years. Over the study period, 67% of all women with a screen-positive result for Down's syndrome had amniocentesis. The uptake rates of amniocentesis varied significantly between women belonging to the two age groups. For women <35 years, 70% of those with a screen-positive result had amniocentesis, whereas among women aged 35, the rate was 61 %. The uptake rate of amniocentesis increased slightly in both groups over the last two years of the study.
Overall, 327 live born babies with Down's syndrome were ascertained in the study population, including 148 with a positive Down's syndrome screening result. Of these 148 births, 57 were born to women aged <35 years, and 91 to women aged~35. Twenty-three cases were diagnosed prenatally, but the women chose to continue the pregnancies. The others were born to women who had declined amniocentesis. The reasons for declining amniocentesis among the 125 women who had a positive screen result and an affected pregnancy were not known.
Screening performance for neural tube defects
Between October 1993 and September 2000, 428,410 women were screened for ONTD. The overall DR for ONTD was 72.7%, with a FPR of 2.0%. One affected pregnancy was diagnosed in every 39 screen-positive women ( Table 3) . Also shown in Table 3 is the incidence of neural tube defects observed in the MSS population. Over the study period, the incidence decreased gradually, and the overall observed incidence was 0.8 per 1000 pregnancies. Table 4 shows the screening performance for anencephaly and spina bifida separately. The DR for anencephaly was 94.2% while the DR for spina bifida was 47.3%. Since the ICD- Table 5 shows the screening performance for trisomy 18 syndrome during the study period. Between October 1993 and September 2000, 125 cases of trisomy 18 were ascertained in the study population, 66 of which were detected by MSS. The overall observed detection rate was 53%, with a false-positive rate of 0.2%. One affected fetus would be diagnosed for every 12 women with a screenpositive result for trisomy 18. After correcting for spontaneous fetal losses (68%) II of affected pregnancies between the second trimester and term, it would be estimated that approximately half of term trisomy 18 pregnancies could be detected through MSS. 
Detection of trisomy 18 syndrome in the MSS programme
Chromosomal aneuploidies other than Down's syndrome and trisomy 18 detected in the MSS programme
Aneuploidies other than Down's syndrome and trisomy 18 were also ascertained in the Ontario MSS population. They included 45,X (Turner syndrome), trisomy 13, triploidy, and other sex chromosome anomalies such as 47,XXY, 47,XXX and 47, XYY (see Table 6 ). Of the 132 aneuploidies, 90 had a positive Down's syndrome screening result and 11 had a positive ONTD screening result, including three with positive screening results for both Down's syndrome and ONTD and one with positive results for both trisomy 18 and ONTD. Fifteen were screen-positive for trisomy 18. The actual DR for each aneuploidy could not be determined in this study since the total numbers of the aneuploidies occurring in the screening population is not clear.
DISCUSSION
Between 1 October 1993 and 30 September 2000, 423,895 women were screened for Down's syndrome in Ontario, using second trimester triple marker screening. These women comprised 48% of the pregnant population. The programme has achieved a term DR of 70.6% for Down's syndrome, with a FPR of 7.2%. The DR and FPR were close to the theoretical values, I but were slightly higher than other jurisdictions because the risk cut-off for a screenpositive result was 1/385 at term.I.13-15 Based on the age distribution of our screening population, we would have expected 671 cases of Down's syndrome at term, and a DR of 78.6% with a false-positive rate of 7.9%. In our programme, 717 cases of Down's syndrome were identified, giving an estimated number of cases at term of 627. The under-ascertainment of affected pregnancies, particularly in women who had a spontaneous fetal loss, might account for the discrepancy between the expected and estimated term numbers of Down's syndrome cases. In our screened population, about 55% of the women were dated by ultrasound, the remainder by LMP.
Prior to the advent of MSS, the main screening method available was maternal age screening, i.e, women ;;.35 years at delivery were screen-positive, while those <35 were screen-negative. In the Ontario screening population, 16% of screened women were aged ;;.35 years. If all women in the screened population used age screening, only 44% of fetuses with Down's syndrome would have been detected prenatally, with 16% of women having amniocentesis. With the implementation of MSS, 74% of cases of Down's syndrome would have been detected, with 7% of women having amniocentesis.
Although the incidence of Down's syndrome increases with advancing maternal age, more cases of Down's syndrome are seen in women under 35 because the majority of pregnant women are from this age group. In our Down's syndrome screening population, 84% of women were <35 years and 56% of the fetuses with Down's syndrome were from this group. With the use of maternal age screening alone, all of the affected pregnancies in this group would have been missed.
In our programme, the DR for Down's syndrome for women ;;.35 years was 85%, and 20% of women in this group had a screen-positive MSS result. While MSS gives a 15 % lower DR than maternal age screening in this age group, the loss in the DR is offset by the markedly reduced number of invasive procedures and procedure-related fetal losses. For example, if all women ;;.35 years had amniocentesis, 68,831 amniocenteses would have been performed in our population, resulting in 344 fetal losses (assuming the fetal loss rate subsequent to amniocentesis is 0.5%). With amniocentesis performed only on women with a positive MSS result, 13,872 women would have had the procedure, with 69 fetal losses. Potentially, over 54,000 amniocenteses and 275 fetal losses have been avoided. Maternal serum screening in Ontario A proportion of women with a positive MSS result for Down's syndrome choose not to have amniocentesis, perhaps because the procedure carries a risk of iatrogenic fetal loss. This decision seem to be more common in womeñ 35 years. In Ontario, women in this age group are eligible to have amniocentesis. It is probable that some older women opted for MSS in order to avoid amniocentesis.
Overall, 72.7% of cases of neural tube defects were detected, with a FPR of 2.0%. The observed DR of ONTD was slightly lower than expected while the FPR was close to the expected value.' We believe that the lower DR of ONTD was caused by an underestimate in the DR for open spina bifida because closed spina bifida births were included in the denominator of the calculation. Our results show that although ultrasound scans are increasingly used to detect birth defects at mid-trimester, MSS still plays an important role in prenatal screening for ONTD.
Over the study period, the incidence of ONTD decreased gradually. A similar trend has been reported in previous studies." It is estimated that in the absence of terminations of these pregnancies, we would expect an incidence of two per 1000 births for ONTD. 17 Less than half of the expected number was observed in our programme. There are a number of possible reasons which might contribute to the discrepancy between the expected and observed incidence. One is that pregnancies with an ONTD diagnosed by ultrasound scan might have been terminated before the screening test was undertaken. Since the MSS database only collected information on women screened, the number of NTD diagnosed prior to MSS was not clear. Another reason is that the increasing use of folic acid supplementation might have effectively reduced the incidence of neural tube defects. In a recent study conducted in Ontario, Gucciardi et al. reported that the total NTD incidence has decreased in recent years from 16.2 per 10,000 in 1995 to 8.6 per 10,000 in 1999. 18 Since the MSS database collected pregnancy outcomes on 94.8% of the screened population, it is unlikely that ONTD were substantially under-reported. Further studies are needed to investigate the extent of the contribution of ultrasound scanning on the diagnosis of ONTD, and the effectiveness of folic acid in the prevention of ONTD in the Ontario population.
Two different screening protocols for trisomy 18 were used during the study period. In the first years of screening, a fixed analyte cut-off protocol was used. It was later changed to a risk cut-off method. Except for 1993-94, when a detection rate of 61.5% was achieved, higher detection rates were seen in the years during which the risk cut-off method was used. Compared with the theoretical values, the DR was slightly lower with the fixed level cut-off method. The FPR was close to the theoretical values with both methods.
A number of aneuploidies other than Down's syndrome and trisomy 18 were detected through MSS. However, since diagnostic procedures were selectively offered to women with positive MSS results, the number of aneuploidies occurring in women with negative results is unclear, particularly for the viable aneuploidies such as sex chromosomal aneuploidies. Our study cannot give the detection rates for these aneuploidies.
The Ontario MSS programme is one of the largest outcome-based serum screening programmes in the world. The results of our study show that MSS has been effective www.jmedscreen.com 111 for prenatal detection of Down's syndrome, ONTD and trisomy 18 in screened women. In addition, MSS screening has markedly decreased the number of invasive procedures in the MSS population. We believe that MSS is an effective and practical method for large-scale second trimester screening for Down's syndrome, ONTD and trisomy 18 and that the MSS database is an effective tool for assessing the performance of this screen and potentially other prenatal screening modalities.
